Abstract
Complicated Staphylococcus aureus infections, including bacteremia, are often associated with treatment failures, prolonged hospital stays, and the emergence of resistance to primary and even secondary therapies. Daptomycin is commonly used as salvage therapy after vancomycin failure for the treatment of methicillin-resistant S. aureus (MRSA) infections. Unfortunately, the emergence of daptomycin resistance, especially in deep-seated infections, has been reported, prompting the need for alternative or combination therapy. Numerous antibiotic combinations with daptomycin have been investigated clinically and in vitro. Of interest, the combination of daptomycin and trimethoprim-sulfamethoxazole (TMP-SMX) has proved to be rapidly bactericidal in vitro to strains that are both susceptible and nonsusceptible to daptomycin. However, to date, there is limited clinical evidence supporting the use of this combination. This was a multicenter, retrospective case series of patients treated with the combination of daptomycin and TMP-SMX for at least 72 h. The objective of this study was to describe the safety and effectiveness of this regimen in clinical practice. The most commonly stated reason that TMP-SMX was added to daptomycin was persistent bacteremia and/or progressive signs and symptoms of infection. After the initiation of combination therapy, the median time to clearance of bacteremia was 2.5 days. Microbiological eradication was demonstrated in 24 out of 28 patients, and in vitro synergy was demonstrated in 17 of the 17 recovered isolates. Further research with this combination is necessary to describe the optimal role and its impact on patient outcomes.
INTRODUCTION
According to the National Healthcare Safety Network (NHSN) at the Centers for Disease Control and Prevention, Staphylococcus aureus remains the most common pathogen causing hospital-acquired infections, and resistance to methicillin remains at >50% (1). In addition, the first documented isolates with decreased susceptibility to vancomycin (vancomycin-intermediate S. aureus) and full resistance to vancomycin were initially reported in 1997 and 2002, respectively (2, 3). Organisms expressing heterointermediate susceptibility to vancomycin, while remaining phenotypically susceptible to vancomycin, have been associated with high vancomycin treatment failure rates (4–6). Currently, there is no consensus regarding optimal treatment; however, the majority of isolates remain susceptible to nonglycopeptide therapies such as daptomycin. Daptomycin is a concentration-dependent cyclic lipopeptide with bactericidal activity against Gram-positive bacterial pathogens (7). Daptomycin susceptibility should be monitored, however, because of the potential association between the presence of heteroresistance to vancomycin and the emergence of daptomycin-nonsusceptible (DNS) isolates (8). Although DNS isolates remain relatively uncommon, there have been increasing reports of patients with complicated, often deep-seated, methicillin-resistant S. aureus (MRSA) infections initially treated with vancomycin where DNS isolates have emerged (9–12).
There is a growing concern regarding clinical failure secondary to DNS isolates, resulting in a need to develop novel treatment modalities (13–18). However, many of the alternatives to daptomycin tend to be bacteriostatic, resulting in less-than-optimal clearance of infections such as infective endocarditis and meningitis (19). Combination therapies with various antimicrobials have been evaluated. One combination, daptomycin plus trimethoprim-sulfamethoxazole (TMP-SMX), appears promising and requires further investigation. Two in vitro simulated endocardial vegetation models compared daptomycin alone and in combination with TMP-SMX against DNS isolates (20, 21). Both models demonstrated that the combination was superior to daptomycin alone or in combination with other agents, such as linezolid and beta-lactams. Clinically, there have been two case reports detailing positive clinical outcomes: one with two patients with vertebral osteomyelitis complicated by MRSA bacteremia and one with a single patient diagnosed with infective endocarditis (22, 23). The Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children recommend the use of high-dose daptomycin in combination with TMP-SMX as one of the alternative therapies for persistent infections with vancomycin treatment failure because of the success of these models (24). Since this guideline recommendation, there have been limited anecdotal reports of its use. This case series comprises the largest collection of patients treated with daptomycin and TMP-SMX that has been published to date.
MATERIALS AND METHODS
Study design and population.
This retrospective, multicenter case series included adult (≥18 years of age) patients from the Detroit Medical Center, Detroit, Michigan, St. Joseph's Hospital Health Center, Syracuse, New York, and St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada, who received the combination daptomycin and TMP-SMX for ≥72 h for the treatment of deep-seated MRSA infections from January 2010 to June 2014. Patients were excluded from the analysis if the causative pathogen was not S. aureus, the primary site of infection was pneumonia, or the patient was receiving TMP-SMX for prophylaxis against Pneumocystis jirovecii pneumonia. A waiver of informed consent was obtained from the participating hospitals' human investigation committees.
Data collection.
Patients' demographics, site of infection, comorbid conditions, antimicrobial exposure in the past 30 days, empirical antimicrobial therapy, concomitant antimicrobial therapy, duration of combination therapy, concurrent surgical interventions, presence of bacteremia, date of clearance of bacteremia (as available), length of hospital stay, 30-day all-cause mortality (as available), and overall clinical outcome as judged by the treating medical team were collected. All data were collected and stored securely via a password-protected REDCap database (25).
Safety assessment.
Safety data included adverse-event reporting by the medical team and independent evaluation of laboratory values, including creatinine phosphokinase (CPK), serum creatinine, and potassium. Reasons for discontinuation of the combination therapy were assessed to determine the relation to the development of an adverse drug event.
Definitions.
Methicillin resistance in S. aureus was defined per the Clinical and Laboratory Standards Institute (CLSI) guidelines as an MIC of ≥4 μg/ml to oxacillin. Daptomycin susceptibility in S. aureus was defined as an MIC of ≤1 μg/ml, and strains with an MIC of >1 μg/ml were referred to as daptomycin nonsusceptible (DNS) (26).
Patient outcomes were categorized as cure, improved, failure, or nonevaluable. Cure was defined as infection clearance, with negative cultures reported, as available, at the end of combination therapy, and resolution of all clinical signs and symptoms with no additional antibiotic therapy necessary. Improvement was defined as a partial resolution of clinical signs and symptoms and/or additional antibiotic therapy necessary at the end of combination therapy. Failure was an inadequate response to daptomycin and TMP-SMX therapy, defined as worsening or new/recurrent signs and symptoms of infection requiring a change in therapy or a positive culture reported at the end of combination therapy. Nonevaluable was defined as cases in which treatment response was unable to be determined at discharge or the end of combination therapy because medical records did not contain appropriate information to determine the clinical outcome.
Safety analysis definitions include adverse effects of either daptomycin or TMP-SMX. CPK elevations possibly caused by daptomycin were defined as >10× the upper limit of normal (ULN) or >5× ULN with symptoms of myopathy. Creatinine elevation was defined as serum creatinine levels with an increase of >1.5× from baseline or a ≥0.5-mg/dl increase in two consecutive measurements. Elevations in potassium secondary to combination therapy were evaluated with the definition of hyperkalemia as >5 meq/liter in the absence of hemolysis.
Susceptibility testing.
Organism susceptibility data and baseline blood isolate data were collected from the electronic medical record. MIC values of studied antimicrobials were determined in duplicate by broth microdilution (BMD) at ∼106 CFU/ml per CLSI guidelines for all recovered isolates studied in time-kill experiments (27). All samples were incubated at 35°C for 18 to 24 h in Mueller-Hinton broth (MHB; Difco, Detroit, MI) supplemented with 50 mg/liter calcium and 12.5 mg/liter magnesium as growth media.
Synergy time-kill experiments.
Time-kill experiments to determine the presence or absence of synergy were performed in duplicate against 17 recovered isolates in MHB supplemented with 50 mg/liter calcium and 12.5 mg/liter magnesium as growth media. Each macrowell received an initial bacterial inoculum of ∼106 CFU/ml. Bacterial strains were exposed to 0.5× their respective MIC values for daptomycin (Cubist Pharmaceuticals, Lexington, MA) and TMP-SMX (Sigma Chemical, St. Louis, MO) for 24 h. Each agent was tested alone and in combination against all available strains. Aliquots of 100 μl were obtained from each well at 0, 4, 8, and 24 h. Each sample was serially diluted to an appropriate concentration and plated using automatic spiral plating (WASP; DW Scientific, West Yorkshire, England). After 18 to 24 h growth on Trypticase soy agar, bacterial colonies were counted using a laser colony counter (ProtoCOL; Synoptics Limited, Frederick, MD). Time-kill curves were generated by plotting mean colony counts (log10 CFU/ml) versus time to compare 24-hour killing effects of antimicrobial exposures. Synergy was defined as a ≥100-fold increase in bacterial killing compared to the most active single constituent. Bactericidal activity was defined as a ≥1,000-fold reduction from baseline.
Statistical analysis.
Patient data (baseline characteristics and clinical outcomes) were analyzed descriptively in terms of numbers, percentages, medians, and interquartile ranges (IQRs). The results of time-kill studies were compared using one-way analysis of variance (ANOVA) with Tukey's post hoc test for comparison of differences among groups. A P value of <0.05 was considered significant.
RESULTS
Twenty-eight patients received the combination of daptomycin and TMP-SMX for the treatment of MRSA infections. Table 1 details patient aggregate demographic and baseline laboratory information. Among the 28 patients, the most common source of infection leading to the use of combination daptomycin and TMP-SMX was bone and joint infections (n = 10, 35.7%). A total of 89.2% (n = 25) received an infectious diseases consult within a median of 2 days of positive blood cultures. Most patients (n = 21, 75.0%) received vancomycin at a median (IQR) maintenance dose of 15.1 mg/kg (13.3 to 16.0 mg/kg) to achieve troughs of 15 to 20 mg/liter prior to the initiation of daptomycin and were changed per hospital policy because of elevated MICs (MIC = 2 μg/ml per automated testing methodology or Etest; n = 17, 60.7%). The median time to daptomycin therapy was 4 days (IQR, 2 to 6 days) and to the addition of TMP-SMX from daptomycin initiation was 5 days (IQR, 1.5 to 9.5 days). Although the reason for combination therapy was not described in many cases (n = 9, 32.1%), the stated reasons included persistent bacteremia (n = 9, 32.1%), evidence of synergy (n = 7, 25.0%), and better central nervous system (CNS) penetration of TMP-SMX (n = 3, 10.7%). The median dose of daptomycin was 9.9 mg/kg daily (IQR, 8.8 to 10.0 mg/kg) and that of TMP-SMX was 8.1 mg/kg daily (IQR, 5.1 to 9.2 mg/kg daily) based on the TMP component.
TABLE 1.
Baseline demographics and laboratory data
| Variablea | Datab |
|---|---|
| Age (yr) | 54 (48–57) |
| Weight (kg) | 73.5 (64.5–82.7) |
| SOFA | 2 (1–6) |
| Daptomycin dose (mg/kg) | 9.9 (8.8–10.0) |
| TMP-SMX dose (mg/kgc) | 8.1 (5.1–9.2) |
| Male | 20 (71.4) |
| Comorbidity | |
| CKD not on CRRT | 4 (14.3) |
| CKD with CRRT | 4 (14.3) |
| Chronic liver disease | 4 (14.3) |
| Diabetes mellitus | 7 (25.0) |
| IVDU | 10 (35.7) |
| Prosthetic hardware/device | 5 (17.8) |
| Prior hospitalization <1 yr | 22 (78.6) |
| Prior reported MRSA infection | 10 (35.7) |
| Prior antibiotics <30 days | 17 (60.7) |
| Primary site of infection | |
| Skin/soft tissue | 8 (28.5) |
| Infective endocarditis | 7 (25.0) |
| Bone/joint | 10 (37.5) |
| Central nervous system | 2 (7.1) |
| Deep abscess | 9 (32.1) |
| Laboratory data | |
| DNS isolates | 6 (21.4) |
| Presence of bacteremia | 26 (92.8) |
| Baseline GFR <30 ml/min | 7 (25.0) |
CKD, chronic kidney disease; CRRT, continuous renal replacement therapy; GFR, glomerular filtration rate; IVDU, intravenous drug use; SOFA, sequential organ failure assessment.
Data are median (IQR) or number (%).
Based on TMP component.
Twenty-six (92.9%) out of 28 patients had positive blood cultures for MRSA during admission. The median total duration of bacteremia was 10 days (IQR, 7 to 16 days). Bacteremia cleared in six patients before or at the time of addition of TMP-SMX; for the remaining patients, bacteremia cleared within a median of 2.5 days (IQR, 1 to 6.75 days) after the initiation of combination therapy. Six isolates were DNS by broth microdilution, and all isolates were susceptible to TMP-SMX. Patients with DNS isolates had cleared bacteremia a median of 6.5 days (IQR, 5 to 7.5 days) after the initiation of TMP-SMX, compared to a median of 2 days (IQR, 1 to 6 days) in those with daptomycin-susceptible isolates. The median length of hospital stay was 24.5 days, and nine patients (33.3%) were admitted to the intensive care unit (ICU) at least once. Twenty-three patients had interventions in addition to antibiotic therapy, the most common being drainage and/or debridement of the source of infection (n = 19, 67.9%). Other interventions included amputation and removal of an infected graft. Among patients who received additional interventions, nine had negative blood cultures upon intervention, and the remainder had a median of 7 days (IQR, 3.5 to 9 days) of bacteremia postintervention. With respect to clinical outcomes, half of the patients had organism eradication without readmission, five patients (17.8%) expired during hospitalization, three (10.7%) were admitted with similar infection-related chief complaints, one (3.5%) was admitted for a nonrelated disease state, and four (14.3%) were lost to follow-up (Table 2). Adverse events relating to the combination of daptomycin and TMP-SMX were not commonly reported. Six patients (21.4%) had an adverse reaction reported in their medical charts (3 CPK elevations, 3 hyperkalemia), of which 50.0% were deemed unlikely to be related to antibiotic therapy. The time to development of adverse events ranged from 0 to 25 days (median, 6.5 days) after the initiation of combination therapy. The median baseline CPK level was 63.0 IU/liter (IQR, 32.7 to 148.3 IU/liter), and the median peak CPK level was 164.0 IU/liter (IQR, 113.0 to 814.0 IU/liter). Two patients had CPK levels of >2,000 IU/liter, but these were their baseline measurements, which decreased during therapy. Ten (35.7%) patients reported electrolyte abnormalities with respect to potassium at a median of 7.5 days after initiation of combination therapy. The median potassium level reported among patients without hemolysis or hemodialysis was 5.1 mg/dl. Among those with reported hyperkalemia, the median potassium level was 5.8 mg/dl. The two highest levels of potassium (6.9 mg/dl and 10.1 mg/dl) were seen in patients with chronic kidney disease on renal replacement therapy, particularly intermittent hemodialysis. All patients had resolution of signs and/or symptoms, and only one patient required discontinuation of TMP-SMX and daptomycin therapy secondary to elevated CPK.
TABLE 2.
Clinical outcomesa
| ID (isolate) | Source | Reason for TMP-SMX | Dose TMP-SMX (TMP component) | Total days of bacteremia (days after TMP-SMX) | Microbiological outcome | Discharge disposition | Reported ADR | Notes |
|---|---|---|---|---|---|---|---|---|
| 1 | IE/septic PE | Persistent bacteremia | 160 mg p.o. Q12 h | 7 (0) | Eradicated | Expired | None | Persistent sepsis with encephalopathy |
| 2 (8449) | Septic arthritis (knee) | Not documented | 360 mg p.o. Q12 h | 2 (NA) | Eradicated | Clinical cure | None | Discharged on OPAT DAP and p.o. TMP-SMX |
| 3 (8541) | Septic arthritis (wrist) | Not documented | 320 mg p.o. Q12 h | 16 (6) | Eradicated | Failure | None | Homeless patient discharged on DAP plus p.o. TMP-SMX for septic arthritis; multiple readmissions within 30 days following noncompliance with therapy |
| 4 | Psoas muscle abscess | Persistent bacteremia | 160 mg p.o. Q24 h | 17 (3) | Eradicated | Expired | CPK >1,000 IU/liter, resolved upon d/c | Changed to CPT; expired shortly after |
| 5 (8591) | Septic arthritis (hip) | Evidence of synergy | 320 mg p.o. Q12 h | 12 (1) | Eradicated | Improved | None | Discharged on OPAT DAP and p.o. TMP-SMX to SNF |
| 6 (7994) | Iliac abscess | Persistent bacteremia | 320 mg p.o. Q12 h | 8 (2) | Eradicated | Improved | None | Discharged on p.o. TMP-SMX, noncompliant |
| 7 (8001) | L2-L3 osteomyelitis | Evidence of synergy | 320 mg p.o. Q12 h | 10 (2) | Eradicated | Clinical cure | None | Concurrent prostatic abscess that was deroofed; sent home on p.o. TMP-SMX |
| 8 (7825) | IE/septic PE | Persistent bacteremia | 320 mg p.o. Q12 h | 7 (NA) | Eradicated | Improved | CPK >2,000 IU/liter at admission | Right hip prosthetic removed, antibiotic spacer with drain; readmitted within 2 weeks for increasing drainage |
| 9 | IE, septic PE, T4 osteomyelitis with epidural abscess | Better CNS penetration (TMP-SMX) | 320 mg p.o. Q8 h | 19 (16) | Eradicated | Improved | None | Admission complicated by cardiac arrest, pacemaker insertion, development of paraplegia, sacral decubitus ulcer with ESBL organism; readmission for sepsis secondary to sacral decubitus ulcer |
| 10 (7397) | T6-T7 osteomyelitis | Progression of epidural abscess | 320 mg p.o. Q12 h | 3 (NA) | Eradicated | Improved | None | Short-term rehabilitation after T6-T7 laminectomy; DAP, TMP-SMX, rifampin therapy for 24 days |
| 11 | C6-C7 epidural abscess, L4-L5 septic arthritis, meningitis | Better CNS penetration (TMP-SMX) | 160 mg p.o. Q12 h | 33 (22) | Eradicated | Improved | None | Also on rifampin during hospital admission; multiple episodes of asystole requiring insertion of pacemaker before discharge to long-term care |
| 12 | C1-C2 septic arthritis, C2 epidural abscess | Not documented | 320 mg p.o. Q12 h | 2 (0) | Eradicated (0) | Improved | None | Treated with DAP, TMP-SMX, rifampin; short-term rehabilitation after C3 to C6 laminectomy |
| 13 | Unknown, possibly HD graft | Evidence of synergy | 160 mg p.o. Q24 h | 10 (8) | Eradicated | Improved | None | Fourth episode MRSA bacteremia of unknown source while on DAP OPAT without removal of graft; graft removed and discharged on CPT and p.o. TMP-SMX |
| 14 (6413) | Bone/joint | Not documented | 320 mg p.o. Q12 h | 1 (NA) | Eradicated | Improved | None | Discharged on OPAT DAP and p.o. TMP-SMX; hyperkalemia episodes after discharge |
| 15 | Bone/joint | Evidence of synergy | 320 mg p.o. Q12 h | 11 (4) | Eradicated | Improved | None | Readmission due to medication noncompliance |
| 16 (6003) | Unknown | Not documented | 160 mg p.o. Q24 h | 3 (NA) | Eradicated | Improved | None | Refused TEE; discharged on OPAT DAP and p.o. TMP-SMX |
| 17 (6408) | L4-L5 osteomyelitis and epidural abscess | Persistent bacteremia | 300 mg i.v. Q12 h | 26 (1) | Eradicated | Improved | Myopathy, no CPK elevation, resolved | Discharged on OPAT DAP and p.o. TMP-SMX to SNF; 30-day infection-related readmission |
| 18 (7162) | Iliopsoas abscesses | Evidence of synergy | 320 mg p.o. Q12 h | 13 (1) | Eradicated | Improved | None | Readmission with persistent fevers, but blood cultures remained negative |
| 19 (7198) | IE, osteomyelitis (foot) | Not documented | 480 mg p.o. Q24 h | 9 (0) | Eradicated | Improved | None | Mitral valve replacement; discharged on OPAT DAP and p.o. TMP-SMX. |
| 20 | Osteomyelitis, septic arthritis (knee) | Not documented | 160 mg p.o. Q12 h | NA | NA | Improved | None | Right AKA prior to discharge; left rehabilitation AMA |
| 21 | Osteomyelitis (hip), prosthetic hardware | Not documented | 320 mg p.o. Q12 h | NA | NA | Improved | None | Removal of right hip hardware; discharged to SNF with p.o. TMP-SMX |
| 22 (F31774) | T9-T10 osteomyelitis/diskitis | Evidence of synergy | 250 mg i.v. Q8 h | 2 (NA) | Eradicated | Clinical cure | None | Discharged on OPAT DAP and p.o. TMP-SMX; no recurrence at 4-year follow-up |
| 23 (H9749-1) | T6-T7 osteomyelitis | Evidence of synergy | 240 mg i.v. Q12 h | 6 (2) | Eradicated | Expired | Hyperkalemia, resolved after discontinuation | Patient experienced dyspnea on day 15 of hospitalization; CT with septic pulmonary emboli; expired |
| 24 | Prosthetic valve IE | Persistent bacteremia | 320 mg i.v. Q24 h | 32 (7) | Unknown | Expired | None | After 4 days of DAP plus TMP-SMX, changed to CPT plus TMP-SMX; No cultures taken between; had NSTEMI and made comfortable |
| 25 | HD graft | Persistent bacteremia | 160 mg p.o. Q24 h | 20 (8) | Persistent | Improved | None | Therapy changed to CPT plus p.o. TMP-SMX with continued bacteremia; cleared only after dialysis graft removal |
| 26 (8687) | IE, HD graft | Persistent bacteremia | 160 mg p.o. Q24 h | 12 (NA) | Eradicated | Improved | CPK >1,000 UI/liter with myopathy | Therapy changed to CPT plus p.o. TMP-SMX because of CPK elevation after bacterial clearance |
| 27 (232977) | IE, septic arthritis (knee) | Resistance | 320 mg p.o. Q12 h | 10, 8 (3) | Eradicated | Cure | None | Developed nonsusceptibility to DAP monotherapy with reemergence of bacteremia before being placed on p.o. TMP-SMX; cleared blood cultures after TMP-SMX |
| 28 (8869) | IE | Persistent bacteremia | 320 mg p.o. Q12 h | 13 (6) | Eradicated | Improved | None | Developed nonsusceptibility while on DAP monotherapy; cleared bacteremia on combination, then switched to CPT before discharge |
ADR, adverse drug reaction; AKA, above-knee amputation; AMA, against medical advice; CNS, central nervous system; CPK, creatinine phosphokinase; CPT, ceftaroline; CT, computed tomography; DAP, daptomycin; DVT, deep vein thrombosis; ESBL, extended-spectrum β-lactamase; IE, infective endocarditis; HD, hemodialysis; i.v., intravenous; NA, not available; NSTEMI, non-ST segment elevation myocardial infarction; OPAT, outpatient parenteral antimicrobial therapy; PE, pulmonary embolism; p.o., oral; Q, every; SNF, skilled nursing facility; TEE, transesophageal echocardiogram.
In vitro time-kill experiments demonstrated that the combination of daptomycin and TMP/SMX was synergistic for 17 of the 17 isolates available for synergy testing (Fig. 1). All isolates were susceptible to TMP-SMX by broth microdilution, while 6 isolates (R6003, R8687, R8869, 232977, SA-H9749-1, and SA-F31774) were nonsusceptible to daptomycin. Of the 6 isolates not susceptible to daptomycin, 5 had a daptomycin MIC value of 4 μg/ml, and 1 (SA-H9749-1) possessed a daptomycin MIC of 2 μg/ml. The combination of daptomycin and TMP-SMX was synergistic and nearly bactericidal against 3 isolates at 24 h (−2.19 ± 0.11, −2.49 ± 0.11, and −2.56 ± 0.01 log10 CFU/ml from initial inoculum for R6003, R8687, and R8869, respectively). The combination was synergistic and bactericidal at 24 h for strains SA-H9749-1, SA-F31774, and 232977 (−3.35 ± 0.03, −3.83 ± 0.08, and −3.27 ± 0.10 log10 CFU/ml, respectively).
FIG 1.
Change in log10 CFU/ml from baseline at 24 h by MRSA strain in time-kill studies. DAP and TMP-SMX were given at 0.5× the MRSA of the respective MRSA strains. Black bars, growth control; white bars, DAP; gray bars, TMP-SMX; checkered bars, DAP + TMP-SMX.
DISCUSSION
This case series describes the treatments and outcomes of patients with serious, deep-seated MRSA infections that could not be successfully managed with conventional therapy and were switched to salvage therapy with the novel combination daptomycin plus TMP-SMX. Previous literature demonstrated positive outcomes using this combination in patients with vertebral osteomyelitis and infective endocarditis (22, 23). In the current series, the types of infections were similar, including infective endocarditis, deep-seated abscesses, and bone/joint infections in the majority of cases. As many of these infections were chronic in nature, clinical cure at discharge was rarely definitively established; however, 50.0% of the patients had organism eradication without readmission. Overall, microbiological eradication was demonstrated in 92.8% of patients, with persistence seen in only one patient that could only be managed with source control. Although the doses of daptomycin varied, all but two patients had doses higher than the current FDA-approved 6 mg/kg/day. This higher dose of daptomycin is consistent with current practice recommendations from the IDSA. The optimal dose of TMP-SMX is still unknown; however, the dose of 8 mg/kg/day to 10 mg/kg/day TMP component demonstrated clinical utility in this case series. Adverse events secondary to the combination were minimal, with only three patients experiencing adverse drug reactions that were determined to be attributable to the treatment and only one requiring discontinuation of therapy. Two of the three patients with a daptomycin MIC of 4 μg/ml expired following a myocardial infarction and development of pulmonary embolism.
In this case series, six isolates were DNS, with daptomycin MICs of 2 μg/ml (n = 1) and 4 μg/ml (n = 5), while all were susceptible to TMP-SMX. Our laboratory was one of the first to publish data on this novel combination for multidrug-resistant MRSA, especially for isolates that are DNS. Using an in vitro simulated endocardial vegetation pharmacokinetic/pharmacodynamic (PK/PD) model, we compared daptomycin 6 mg/kg every 24 h alone and in combination with TMP-SMX 160/800 mg every 12 h, linezolid 600 mg every 12 h, cefepime 2 g every 12 h, or nafcillin 4 g every 4 h in two DNS isolates (20). The combination of daptomycin and TMP-SMX proved to be significantly superior to daptomycin alone and was the only regimen to sustain significant bactericidal activity over the 72-hour model. In another simulated endocardial vegetation PK/PD model, the activities of high-dose daptomycin and TMP-SMX were studied alone and in combination against four DNS isolates (21). The regimens studied included daptomycin 10 mg/kg every 24 h for 14 days, TMP-SMX 160/800 mg every 12 h for 14 days, a combination of the two for 14 days, or a combination for 7 days followed by deescalation to one of the antibiotics of interest. The combinations for 14 days or for 7 days followed by deescalation to either daptomycin or TMP-SMX were significantly better than daptomycin monotherapy. Echoing previously published data, synergy occurred in 17 of the 17 isolates tested in this study via time-kill methods. Perhaps most important, synergy extended to the DNS isolates, establishing the efficacy of the daptomycin and TMP-SMX combination against difficult-to-treat strains in vitro. Additionally, previous literature highlighted the importance of TMP-SMX susceptibility in order for the combination to work synergistically (4).
Previous studies evaluated the combination of daptomycin and beta-lactams with positive results (28–34). The combination of daptomycin with rifampin was also evaluated, especially in hardware-associated infections (23, 35–39). Several other agents have been studied with limited applicability in the United States. For instance, the combination of daptomycin with fosfomycin was shown to be favorable, but the intravenous form is not available in the United States (40–42). Published literature on the combination of daptomycin and TMP-SMX is scarce. A case report using high-dose TMP-SMX (15 mg/kg daily TMP component) intravenously in combination with daptomycin at 8 mg/kg demonstrated clinical improvement and microbiological clearance of infective endocarditis that was complicated by embolic stroke (23). After 6 weeks of the combination, the patient was discharged on high-dose TMP-SMX for an additional 6 weeks without complication. Clinical practice guidelines by the IDSA for the treatment of MRSA infections in adults and children recommend using doses of daptomycin greater than those that are currently approved by the FDA in combination with TMP-SMX for persistent infections with vancomycin treatment failure due to the previously mentioned reports, primarily consisting of in vitro data with only several clinical case reports. The recommendation to use this combination in the face of scarce data is secondary to the wide variety of treatment options and the difficulty in successfully treating these patients. Publication of the current study expands the available body of literature to support the recommendation and provides the largest study population to date.
The findings in this retrospective case series are promising, with a high rate of microbiological eradication found in DNS and non-DNS strains. Additionally, the combination demonstrated low rates of toxicity without persistence. The combination of once-daily intravenous daptomycin and oral TMP-SMX allows for ease of administration as an outpatient regimen. Additional investigation into the long-term follow-up of patients with infective endocarditis and bone and joint infections is needed. As more clinicians use this regimen, a larger body of literature can be compiled to determine which patients are optimally amenable to this combination. In addition, it may be of interest to explore the clinical utility of TMP-SMX in other antimicrobial combinations for difficult-to-treat infections.
REFERENCES
- 1.Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities . 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 34:1–14. doi: 10.1086/668770. [DOI] [PubMed] [Google Scholar]
- 2.Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670–1673. doi: 10.1016/S0140-6736(97)07324-8. [DOI] [PubMed] [Google Scholar]
- 3.Abadia Patino L, Courvalin P, Perichon B. 2002. vanE gene cluster of vancomycin-resistant Enterococcus faecalis BM4405. J Bacteriol 184:6457–6464. doi: 10.1128/JB.184.23.6457-6464.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Werth BJ, Rahman SM, Szeliga AP, Rose WE, Rybak MJ. 2013. Exploring the mechanism of synergy between daptomycin (DAP) and trimethoprim/sulphamethoxazole (TMP/SMX) against methicillin-resistant Staphylococcus aureus (MRSA). 23rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Berlin, Germany. [Google Scholar]
- 5.van Hal SJ, Paterson DL. 2011. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 55:405–410. doi: 10.1128/AAC.01133-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. 2013. Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bloodstream infection. Antimicrob Agents Chemother 57:4252–4259. doi: 10.1128/AAC.00380-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Cubist Pharmaceuticals. 2003. Cubicin: highlights of prescribing information. Cubist Pharmaceuticals, Lexington, MA: http://cubicin.com/pdf/PrescribingInformation.pdf. [Google Scholar]
- 8.Kelley PG, Gao W, Ward PB, Howden BP. 2011. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 66:1057–1060. doi: 10.1093/jac/dkr066. [DOI] [PubMed] [Google Scholar]
- 9.Velazquez A, Deryke CA, Goering R, Hoover V, Wallace MR. 2013. Daptomycin non-susceptible Staphylococcus aureus at a US medical centre. Clin Microbiol Infect 19: 1169–1172. doi: 10.1111/1469-0691.12171. [DOI] [PubMed] [Google Scholar]
- 10.Jongsma K, Joson J, Heidari A. 2013. Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report. J Antimicrob Chemother 68:1444–1445. doi: 10.1093/jac/dkt009. [DOI] [PubMed] [Google Scholar]
- 11.Hsu LY, Leong M, Balm M, Chan DS, Huggan P, Tan TY, Koh TH, Hon PY, Ng MM. 2010. Six cases of daptomycin-non-susceptible Staphylococcus aureus bacteraemia in Singapore. J Med Microbiol 59:1509–1513. doi: 10.1099/jmm.0.022533-0. [DOI] [PubMed] [Google Scholar]
- 12.Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, Gold HS, Baden LR, Pillai SK. 2006. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 44:595–597. doi: 10.1128/JCM.44.2.595-597.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Kuo CC, Wu VC, Huang YT, Liao CH, Hsueh PR. 2009. Fatal bacteraemia caused by daptomycin-non-susceptible, vancomycin-intermediate, methicillin-resistant Staphylococcus aureus in a patient with chronic kidney disease. Int J Antimicrob Agents 33:96–98. doi: 10.1016/j.ijantimicag.2008.06.028. [DOI] [PubMed] [Google Scholar]
- 14.Moise PA, North D, Steenbergen JN, Sakoulas G. 2009. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 9:617–624. doi: 10.1016/S1473-3099(09)70200-2. [DOI] [PubMed] [Google Scholar]
- 15.Skiest DJ. 2006. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44:655–656. doi: 10.1128/JCM.44.2.655-656.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Vikram HR, Havill NL, Koeth LM, Boyce JM. 2005. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 43:5384–5387. doi: 10.1128/JCM.43.10.5384-5387.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. 2005. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 43:5285–5287. doi: 10.1128/JCM.43.10.5285-5287.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Huang YT, Hsiao CH, Liao CH, Lee CW, Hsueh PR. 2008. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J Clin Microbiol 46:1132–1136. doi: 10.1128/JCM.01844-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Finberg RW, Moellering RC, Tally FP, Craig WA, Pankey GA, Dellinger EP, West MA, Joshi M, Linden PK, Rolston KV, Rotschafer JC, Rybak MJ. 2004. The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis 39:1314–1320. doi: 10.1086/425009. [DOI] [PubMed] [Google Scholar]
- 20.Steed ME, Vidaillac C, Rybak MJ. 2010. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother 54:5187–5192. doi: 10.1128/AAC.00536-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Steed ME, Werth BJ, Ireland CE, Rybak MJ. 2012. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother 56:5709–5714. doi: 10.1128/AAC.01185-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Avery LM, Steed ME, Woodruff AE, Hasan M, Rybak MJ. 2012. Daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 56:5990–5993. doi: 10.1128/AAC.01046-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Di Carlo P, D'Alessandro N, Guadagnino G, Bonura C, Mammina C, Lunetta M, Novo S, Giarratano A. 2013. High dose of trimethoprim-sulfamethoxazole and daptomycin as a therapeutic option for MRSA endocarditis with large vegetation complicated by embolic stroke: a case report and literature review. Infez Med 21:45–49. [PubMed] [Google Scholar]
- 24.Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52:285–292. doi: 10.1093/cid/cir034. [DOI] [PubMed] [Google Scholar]
- 25.Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. 2009. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377–381. doi: 10.1016/j.jbi.2008.08.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Clinical and Laboratory Standards Institute. 2010. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—9th ed. CLSI M7-A9 Clinical and Laboratory Standards Institute, Wayne, PA. [Google Scholar]
- 27.Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA. [Google Scholar]
- 28.Rand KH, Houck HJ. 2004. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 48:2871–2875. doi: 10.1128/AAC.48.8.2871-2875.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. 2011. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 53:158–163. doi: 10.1093/cid/cir340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, Rosato RR, Rosato AE. 2012. β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 56:6192–6200. doi: 10.1128/AAC.01525-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. 2013. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 57:66–73. doi: 10.1128/AAC.01586-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Rose WE, Schulz LT, Andes D, Striker R, Berti AD, Hutson PR, Shukla SK. 2012. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 56:5296–5302. doi: 10.1128/AAC.00797-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Moise PA, Amodio-Groton M, Rashid M, Lamp KC, Hoffman-Roberts HL, Sakoulas G, Yoon MJ, Schweitzer S, Rastogi A. 2013. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant beta-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother 57:1192–1200. doi: 10.1128/AAC.02192-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Garrigos C, Murillo O, Lora-Tamayo J, Verdaguer R, Tubau F, Cabellos C, Cabo J, Ariza J. 2012. Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 56:3806–3811. doi: 10.1128/AAC.00127-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Lin SY, Ho MW, Liu JH, Liu YL, Yeh HC, Hsieh TL, Wang IK, Lin HH, Huang CC. 2011. Successful salvage of peritoneal catheter in unresolved methicillin-resistant Staphylococcus aureus peritonitis by combination treatment with daptomycin and rifampin. Blood Purif 32:249–252. doi: 10.1159/000328028. [DOI] [PubMed] [Google Scholar]
- 36.Saleh-Mghir A, Muller-Serieys C, Dinh A, Massias L, Cremieux AC. 2011. Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 55:4589–4593. doi: 10.1128/AAC.00675-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Garrigos C, Murillo O, Euba G, Verdaguer R, Tubau F, Cabellos C, Cabo J, Ariza J. 2010. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 54:5251–5256. doi: 10.1128/AAC.00226-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Lefebvre M, Jacqueline C, Amador G, Le Mabecque V, Miegeville A, Potel G, Caillon J, Asseray N. 2010. Efficacy of daptomycin combined with rifampicin for the treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Int J Antimicrob Agents 36:542–544. doi: 10.1016/j.ijantimicag.2010.07.008. [DOI] [PubMed] [Google Scholar]
- 39.Antony SJ. 2006. Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus. Scand J Infect Dis 38:293–295. doi: 10.1080/00365540500372697. [DOI] [PubMed] [Google Scholar]
- 40.Miro JM, Entenza JM, Del Rio A, Velasco M, Castaneda X, Garcia de la Maria C, Giddey M, Armero Y, Pericas JM, Cervera C, Mestres CA, Almela M, Falces C, Marco F, Moreillon P, Moreno A, Hospital Clinic Experimental Endocarditis Study Group . 2012. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 56:4511–4515. doi: 10.1128/AAC.06449-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Poeppl W, Tobudic S, Lingscheid T, Plasenzotti R, Kozakowski N, Lagler H, Georgopoulos A, Burgmann H. 2011. Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Antimicrob Agents Chemother 55:4999–5003. doi: 10.1128/AAC.00584-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Chen LY, Huang CH, Kuo SC, Hsiao CY, Lin ML, Wang FD, Fung CP. 2011. High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report. BMC Infect Dis 11:152. doi: 10.1186/1471-2334-11-152. [DOI] [PMC free article] [PubMed] [Google Scholar]